Compare FEIM & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEIM | HBIO |
|---|---|---|
| Founded | 1961 | 1901 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.9M | 26.5M |
| IPO Year | 1994 | 2000 |
| Metric | FEIM | HBIO |
|---|---|---|
| Price | $85.05 | $7.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $51.50 | $18.00 |
| AVG Volume (30 Days) | ★ 282.0K | 15.6K |
| Earning Date | 03-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | $63,227,000.00 | ★ $116,176,000.00 |
| Revenue This Year | N/A | $4.77 |
| Revenue Next Year | $21.73 | $8.55 |
| P/E Ratio | $217.07 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.05 | $0.38 |
| 52 Week High | $89.76 | $8.40 |
| Indicator | FEIM | HBIO |
|---|---|---|
| Relative Strength Index (RSI) | 64.28 | N/A |
| Support Level | $53.71 | N/A |
| Resistance Level | $89.76 | N/A |
| Average True Range (ATR) | 4.31 | 0.00 |
| MACD | 2.19 | 0.00 |
| Stochastic Oscillator | 87.35 | 0.00 |
Frequency Electronics Inc is a world leader in precision time and frequency generation technology, which is incorporated into commercial and U.S. Government satellites, Command, Control, Communication, Computer, Intelligence, Surveillance and Reconnaissance, and Electronic Warfare systems. Its technology is used for a wide range of space and non-space applications. The company has two segments FEI-NY, and FEI-Zyfer. Majority of revenue come from FEI-NY which provides precision time, frequency generation and synchronization products and subsystems that are found on-board satellites, in ground-based communication systems and imbedded in mobile platforms operated by the U.S. military.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.